Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486234 · ClinicalTrials.gov registry record · NA
CARS: Cannabis and Alcohol Reduction Study
A NA study of Substance Use Disorders and Substance Use, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05486234: Recruiting NA study of Substance Use Disorders and Substance Use, sponsored by Medical University of South Carolina.
NCT05486234 is a NA study of Substance Use Disorders and Substance Use that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 52 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486234, a NA study of Substance Use Disorders and Substance Use, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and/or cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.
Primary Outcome
The TLFB is a calendar-assisted semi-structured interview that will be used to assess cannabis and alcohol use since the last assessment. The TLFB will assess the number of days a person used cannabis over the past 90 days compared to the 90 days prior to enrolling in this study.
Conditions Studied
Interventions
- BEHAVIORAL modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias
- BEHAVIORAL modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2026-08-01 |
| Phase | NA |
What NCT05486234 shows while recruiting
NCT05486234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias is the first listed.
NCT05486234 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT05486234 about?
NCT05486234 is a clinical study titled "CARS: Cannabis and Alcohol Reduction Study". The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and/or cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.
What is the current status of trial NCT05486234?
This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2023-01-25. Estimated completion is 2026-08-01.
What conditions does trial NCT05486234 study?
This clinical trial studies the following conditions: Substance Use Disorders, Substance Use, Cannabis Use, Alcohol Use, Unspecified.
What interventions are being tested in trial NCT05486234?
The interventions under investigation include: modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias (BEHAVIORAL), modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias. (BEHAVIORAL).
Who is sponsoring clinical trial NCT05486234?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486234 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486234's enrollment target sits among peer trials
52 67th of 93 higher than 27 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI